Announcements Trials

Browse Landscape

Phase

Phase 1/2 3 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 32 Breast Neoplasms 25 Parkinson Disease 4, Autosomal Dominant Lewy Body 19 Multiple Myeloma 13 Neoplasms 12 Leukemia, Myeloid, Acute 12 Ovarian Neoplasms 10 Neoplasm Metastasis 10 Leukemia, Lymphocytic, Chronic, B-Cell 10 Carcinoma, Renal Cell 10 Prostatic Neoplasms 8 Colorectal Neoplasms 8 Melanoma 7 Lymphoma, Non-Hodgkin 7 Leukemia 7 Stomach Neoplasms 6 Recurrence 6 Fallopian Tube Neoplasms 6 Carcinoma, Hepatocellular 6 Carcinoma 6 Urinary Bladder Neoplasms 5 Small Cell Lung Carcinoma 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Lymphoma 5 Adenocarcinoma 5 Purpura, Thrombocytopenic, Idiopathic 4 Myelodysplastic Syndromes 4 Lymphoma, Follicular 4 Liver Neoplasms 4 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4

Interventions

vandetanib 1 selpercatinib 1 cabozantinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Has announcements × Carcinoma, Medullary × Clear all

NCT04211337 2026-03-19

LIBRETTO-531

Eli Lilly and Company

Phase 3 Active not recruiting

291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡